Advancing mCSPC Treatment: A Closer Look at ADT + Darolutamide with Dr. Rana McKay

For patients with metastatic castration-sensitive prostate cancer (mCSPC), combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARis) has been shown to extend the | Dr. Rana McKay speaks to the ARANOTE trial of NUBEQA® (darolutamide) and what the data mean for patients, doctors, and care providers.